Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by AstraZeneca
< Previous
1
2
3
4
5
6
Next >
CORRECTING and REPLACING ENHERTU® granted Priority Review in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
January 17, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Enhertu Granted Priority Review in the US for Patients With HER2-Positive Metastatic Breast Cancer Treated With a Prior Anti-HER2-Based Regimen
January 17, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca Aims to Redefine Liver, Biliary Tract and Prostate Cancer Treatment With Practice-Changing IMFINZI® (durvalumab) and LYNPARZA® (olaparib) Data at ASCO GI and GU
January 13, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
TEZSPIRE Now Available in the United States for the Treatment of Severe Asthma
January 13, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Inaugural Asia Summit on Global Health successfully explores healthcare landscape
November 25, 2021
From
AstraZeneca
Via
ACN Newswire
Inaugural Asia Summit on Global Health opens today
November 24, 2021
From
AstraZeneca
Via
ACN Newswire
Inaugural Asia Summit on Global Health highlights Hong Kong's advantages
November 17, 2021
From
AstraZeneca
Via
ACN Newswire
EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in studies from Oxford and Washington Universities
December 23, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
TEZSPIRE (tezepelumab) Approved in the US for Severe Asthma
December 17, 2021
From
AstraZeneca
Via
Business Wire
EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in independent FDA study
December 16, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
CALQUENCE reduced the risk of disease progression or death by 71% vs. standard of care combinations at three years in the ASCEND Phase III trial
December 12, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Additional Analyses Further Reinforce Ground-breaking Efficacy in Patients With HER2-positive Metastatic Breast Cancer
December 09, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
EVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19
December 08, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca Reinforces Leadership in Breast Cancer at SABCS 2021 With New Data Underscoring Ambition to Redefine Cancer Care
December 03, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
LYNPARZA® (olaparib) Granted Priority Review in the US for BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer
November 30, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
New Analyses of Two AZD7442 COVID-19 Phase III Trials in High-Risk Populations Confirm Robust Efficacy and Long-Term Prevention
November 18, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
LOKELMA® Granted Fast Track Designation in the US to Reduce Cardiovascular Outcomes in Patients on Chronic Hemodialysis With Hyperkalemia
November 17, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca Advances Ambition to Redefine Care for Blood Cancer at ASH 2021
November 05, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
SAPHNELO Consistently Reduces Systemic Lupus Erythematosus Disease Activity Regardless of Disease Duration and Prior Treatment
November 01, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca Awards 30 Nonprofit Organizations through the ACT on Health Equity Community Solutions Challenge to Actively Address Health Disparities
November 01, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI Plus Chemotherapy Significantly Improved Overall Survival in 1st-Line Advanced Biliary Tract Cancer in TOPAZ-1 Phase III Trial at Interim Analysis
October 25, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca and Bob Harper Unveil the Survivors Have Heart Second Chance Portraits to Change the Face of Heart Attack Survivorship
October 21, 2021
From
AstraZeneca
Via
Business Wire
AstraZeneca Announces Winners and Recognizes Oncology Change Makers in Third Annual Cancer Community Awards
October 20, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI Plus Tremelimumab Significantly Improved Overall Survival in HIMALAYA Phase III Trial in 1st-Line Unresectable Liver Cancer
October 15, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Tezepelumab granted Orphan Drug Designation in the US for eosinophilic esophagitis
October 08, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AZD7442 Request for Emergency Use Authorization for COVID-19 Prophylaxis Filed in US
October 05, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Granted Breakthrough Therapy Designation in US for Patients with HER2-Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens
October 04, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca COVID-19 and RSV presentations at IDWeek 2021 will showcase scientific progress in infectious diseases
September 27, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
LYNPARZA® (olaparib) in combination with abiraterone significantly delayed disease progression in all-comers in PROpel Phase III trial in 1st-line metastatic castration-resistant prostate cancer
September 24, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer
September 18, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.